Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

University of Bristol

- PMLiVE

Novo Nordisk’s new insulin moves closer to US approval

Follows recommendation in Europe

- PMLiVE

Boehringer-Lilly win expanded European licence for Trajenta

Type 2 diabetes drug approved as add-on to insulin in adults

- PMLiVE

Diabetes care recognised at UK awards

Joint working between pharma, NHS and patient organisations key among winners at QiC Diabetes 2012

- PMLiVE

Novo wins CHMP backing for Tresiba and diabetes first

EMA advisors recommend approval of once-daily at unique higher strength

- PMLiVE

Abbott stops kidney disease drug trial on safety concerns

Concerns about excess serious adverse events and mortality in patients taking bardoxolone methyl

- PMLiVE

AZ pays $273m for Ardelyx renal disease drug

Phase II candidate could tackle fluid overload in kidney and heart disorders

- PMLiVE

NICE in U-turn on Novartis’ Lucentis in diabetic macular oedema

Patient access scheme influences draft recommendation

- PMLiVE

Merck & Co says Januvia follow-up looking good

Diabetes drug shows promise in phase II as once-weekly treatment

JDRF and Lilly take diabetes education to secondary schools

The partnership will use a new resource to teach students about type 1 diabetes

Novo Nordisk invests $100m in research in China

Expands existing site in Beijing

Novartis building

CHMP backs trio of Novartis products

Including two diabetes drugs and one for non-cancerous kidney tumours

Diabetes apps present usability problems for older adults

Researchers find a range of potential design problems with smartphone apps

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links